{"id":19360,"date":"2022-01-12T14:29:11","date_gmt":"2022-01-12T19:29:11","guid":{"rendered":"https:\/\/medicarereport.org\/?p=19360"},"modified":"2022-01-12T14:29:12","modified_gmt":"2022-01-12T19:29:12","slug":"medicare-plans-to-restrict-access-to-controversial-pricey-alzheimers-drug-aduhelm-to-patients-in-clinical-trials","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=19360","title":{"rendered":"Medicare plans to restrict access to controversial, pricey Alzheimer\u2019s drug Aduhelm to patients in clinical trials"},"content":{"rendered":"\n<p>(By Rachel Cohrs for ST<em>A<\/em>T)<\/p>\n\n\n\n<p>WASHINGTON \u2014 Medicare plans to cover the controversial, pricey Alzheimer\u2019s drug Aduhelm, but only for certain patients enrolled in clinical trials, the agency announced on Tuesday.  Continue reading <a href=\"https:\/\/www.statnews.com\/2022\/01\/11\/medicare-aduhelm-proposed-decision\/\" data-type=\"URL\" data-id=\"https:\/\/www.statnews.com\/2022\/01\/11\/medicare-aduhelm-proposed-decision\/\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"21\" class=\"wp-image-4372\" style=\"width: 200px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/p>\n\n\n\n<pre class=\"wp-block-preformatted\"><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Rachel Cohrs for STAT) WASHINGTON \u2014 Medicare plans to cover the controversial, pricey Alzheimer\u2019s drug Aduhelm, but only for<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,6,15],"tags":[],"class_list":["post-19360","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-medicare-general","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19360"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19360\/revisions"}],"predecessor-version":[{"id":19361,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19360\/revisions\/19361"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}